PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/
← Fund Intelligence
DOSSIER // VERIFIED INTEL

Catapult Ventures

LeicesterCATAPULT-VENTURES
0
Truth Cards
0
Partners Rated
Avg Score
Get Access
Access Level
◈ Truth Cards
0 VERIFIED

No verified intel yet.
Be the first founder to leave a truth card.

Request Founder Access →
Dossier Summary

No summary available yet.

Classification
Slugcatapult-ventures
HQLeicester
Stage FocusThe fund specializes in providing equity capital between …
Intel StatusAccepting submissions
🔥 BERNIE'S HOT TAKE

This is classic old-school UK venture capital - the kind that's been around since 1999 and has the battle scars to prove it. They've delivered solid returns with 14 profitable exits since 2015 averaging 4.7x, including some standout wins like R2C Online at 12.6x and Accutronics at 9.1x. What's refreshing is they actually take board seats and get their hands dirty - each partner has direct portfolio responsibility and they're not afraid to help with hiring, customer introductions, and financial strategy. With £130m under management, they're mid-sized but experienced. The downside? They're a small team (2-10 employees) which means limited bandwidth, and their heavy life sciences focus means if you're not in healthcare/biotech, you're probably not their cup of tea. They seem genuinely committed to long-term value creation rather than quick flips, which is either exactly what you want or frustratingly slow depending on your timeline.

KEY TAKEAWAYS
  • Best for: Life sciences/healthcare startups wanting experienced, hands-on board members who stick around
  • Watch out for: Small team means limited bandwidth; heavy UK regional focus may limit global connections
  • Known for: Solid track record with 4.7x average returns and genuine operational support post-investment
Investment Thesis

Catapult Ventures focuses on healthcare, medical devices, pharmaceuticals, luxury consumer brands, manufacturing, and software across all stages from start-ups and pre-revenue IP developers to company flotation and billions of pounds in revenue. Their approach centers on value creation through long-term relationships with portfolio companies and fund investors.

Stage & Sector Focus

The fund specializes in providing equity capital between £50k and £2m, with 30 seed-stage investments averaging $1.44M, 19 Series A investments averaging $4.62M, and 5 Series B investments averaging $11.2M. Their actual portfolio spans Life Sciences, HealthTech, High Tech, Enterprise Applications, and Healthcare, showing a strong bias toward life sciences and medical technology.

Notable Portfolio
AccutronicsYospaceAbzenaMonica HealthcareOxford CryosystemsphsR2C OnlinePanthera Biopartners
Key Partners
Professor Rob Carroll
Partner

Industry focus on Digital Healthcare Technology. Part of what they describe as among the most experienced venture capital investors in the UK. Limited public information available about specific background details.

Have a specific question about Catapult Ventures?

Ask Bernie →
INVESTOR ACCESS PERMANENTLY DENIEDBERNBOOK // DOSSIER v1